A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. - Wikidata - wikimedia - TriplyDB

A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.

A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.

http://www.wikidata.org/entity/Q34898930

about

Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer Progress of molecular targeted therapies for prostate cancers Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers Targeting the adaptive molecular landscape of castration-resistant prostate cancer Heat shock and other apoptosis-related proteins as therapeutic targets in prostate cancer Identification, design and bio-evaluation of novel Hsp90 inhibitors by ligand-based virtual screening Identification of the plant compound geraniin as a novel Hsp90 inhibitor Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer Hsp90 blockers inhibit adipocyte differentiation and fat mass accumulation The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins.Acetylation of androgen receptor by ARD1 promotes dissociation from HSP90 complex and prostate tumorigenesis.Synergistic administration of photothermal therapy and chemotherapy to cancer cells using polypeptide-based degradable plasmonic matrices.Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells.Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors Targeting the 90 kDa heat shock protein improves photodynamic therapy.Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics.Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease.Macrocyclic inhibitors of hsp90 Castration-resistant prostate cancer: new science and therapeutic prospects.Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer Topically applied Hsp90 inhibitor 17AAG inhibits UVR-induced cutaneous squamous cell carcinomas Hsp90 inhibitor can inhibit UV carcinogenesis.The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies.BCAS2 promotes prostate cancer cells proliferation by enhancing AR mRNA transcription and protein stability.17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition.The HSP90 inhibitor 17-PAG effectively inhibits the proliferation and migration of androgen-independent prostate cancer cells Novel interaction between the co-chaperone Cdc37 and Rho GTPase exchange factor Vav3 promotes androgen receptor activity and prostate cancer growth.Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.Heat shock proteins in the retina: Focus on HSP70 and alpha crystallins in ganglion cell survival.HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer.Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.Novel targets in esophageal and gastric cancer: beyond antiangiogenesis.Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies.Glucocorticoid Receptor-Targeted Liposomal Codelivery of Lipophilic Drug and Anti-Hsp90 Gene: Strategy to Induce Drug-Sensitivity, EMT-Reversal, and Reduced Malignancy in Aggressive Tumors.Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls.

P2860

Q26750620-750C2129-0496-43C3-8136-8046C95BFE34 Q26823014-E21F930A-5691-4CF0-AC5C-210E44C49222 Q27022514-9B752096-C792-440E-BC5E-9CA1ABFBC67B Q27022821-0FF0C146-D8F4-4E5C-94D1-4FF25380643E Q27026128-5C1B0C3A-CAE6-4B94-9CEE-87A444DEA101 Q28485925-8494182A-BC6C-4F65-8F15-C45E917EF386 Q28533486-822B6985-A3BD-4D23-8B8A-360CF1A38033 Q28541342-3A4140ED-2B87-478B-BF40-98FB07309E4C Q28542000-16FF8F00-11A2-4EBE-8539-AAE206AF0FF4 Q28730558-9F67428B-A1E8-4755-8B11-B40536ADAD08 Q28829301-FD81D994-8865-4EF4-9F3F-99BD2630DE12 Q30244818-D0C2CD76-1931-4338-BB37-2F77F0DBF45E Q30353562-9EDBFCE1-6F15-47A6-AB3E-C71E6427DCFB Q30533630-FBFE413F-0275-4573-928B-1B81CEEB7E9E Q31039889-D844C0C2-7F85-403E-8034-160C8D4B5D51 Q33387877-FC42A812-FC27-4A57-B05A-019044FB5B52 Q33691235-A66AAE92-54FC-43B0-B04C-7D1CFADF0C44 Q34102029-D5B48721-C6E8-4647-80F3-6E0783818E3C Q34140962-2F750F65-C137-452D-A733-C190B4FBE204 Q34164027-6CA31DBF-34B8-488A-9F7D-E4B4E88FFEC0 Q34628001-FD5F22B5-4E8E-439F-A732-96A835AE2321 Q35017513-041E6893-80D4-4D9A-9642-3C9E32BEF65A Q35076264-4D616589-0790-4489-8B6C-01D8472EB107 Q35194754-F5896B56-1DFB-477C-9B49-C512AA83AE45 Q35196261-6AD9C886-A581-4DD2-B4F4-96274BC7BF2B Q35199189-27197857-C972-49D0-9530-BF4047859BC1 Q35444159-11D09A54-D5E9-4D4B-96E2-5DBAD5036C55 Q35677312-0A30EE7F-2792-4378-9F83-8CB353C47887 Q35849973-047612BE-B581-4040-8FE1-C00F272A571C Q36309425-EFBFAE86-718F-49BB-971F-B5BE1AED5AD9 Q36635865-DD5C35E9-8DD6-438F-89F9-AD908885B151 Q36642876-67F17B4B-8CFF-48BC-AFD4-4A58428021F2 Q36829093-0A48C09E-52D2-4F8F-A446-205128C87900 Q37484581-FBDFC3A5-C320-4296-9F54-A156C614CD25 Q37494634-3F7DE268-95BD-4752-A0C5-94A7A17D7C48 Q37566645-14757F35-0FF8-457C-8C3F-FF46D57586A6 Q37594553-C084C43A-F40B-457C-9290-1385BD98D0B2 Q37644744-B6746C05-F949-4E96-860C-0E09DDCB9BA4 Q37737611-B2E33DC0-7F15-44C1-93D4-8585D24901B6 Q37772399-B4F7176B-1F97-4FCC-8016-5DEAE07A1470

P2860

A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.

http://www.wikidata.org/entity/Q34898930

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

name

A phase II trial of 17-allylam ...... ry metastatic prostate cancer.

@ast

A phase II trial of 17-allylam ...... ry metastatic prostate cancer.

@en

A phase II trial of 17-allylam ...... ry metastatic prostate cancer.

@nl

type

label

A phase II trial of 17-allylam ...... ry metastatic prostate cancer.

@ast

A phase II trial of 17-allylam ...... ry metastatic prostate cancer.

@en

A phase II trial of 17-allylam ...... ry metastatic prostate cancer.

@nl

prefLabel

A phase II trial of 17-allylam ...... ry metastatic prostate cancer.

@ast

A phase II trial of 17-allylam ...... ry metastatic prostate cancer.

@en

A phase II trial of 17-allylam ...... ry metastatic prostate cancer.

@nl

P1433

Q34898930-2CBD7C20-9E3F-406A-858A-A472201D4AEC

P1476

Q34898930-12BD35CB-1871-4E22-B30E-CAA93CAEE578

P2093

Q34898930-179B5163-A5C4-4BF9-A099-4B539C2C2E4A

Q34898930-31399ED6-9C1E-430E-AEB5-5160E011FB1C

Q34898930-3B37BB0B-AA23-478E-B4BD-7588866EF72B

Q34898930-3F8F4A4E-CF54-4786-9D75-A6042A53E300

Q34898930-4371B580-E8CE-42DD-918E-15E234DF0B34

Q34898930-44593041-09C8-463A-AB83-6F424F4DD150

Q34898930-556F43BF-3C1C-4B55-AD83-D3303CD0572F

Q34898930-58F8265D-9178-4D36-9DD8-C17782B8B784

Q34898930-6F925D36-E404-4294-B012-25D75DF1FEB6

Q34898930-7D9C3242-FE6B-44F9-BA94-C984C09F1379

P2860

Q34898930-23ACD148-02D7-47C4-9711-53CBD04B09B3

Q34898930-2C99E5DC-ACFF-4E6B-A5D0-CBD46CFBBDD1

Q34898930-36A55695-8BE6-45F5-A502-A2051F9439B6

Q34898930-3C770148-D829-4826-93BC-DB25BEF7EDDA

Q34898930-57688AA3-0E97-4DAA-A18C-1FBA19DD9591

Q34898930-618FEA36-5746-4B86-BB3C-6994030C9F9C

Q34898930-66BD71F8-4F4D-442B-9A48-9B57B1DE9E06

Q34898930-6897ADC6-44A5-4F2F-95B3-94B432AEA1EE

Q34898930-6D68767F-07DC-4033-BD87-640966AEA118

Q34898930-76CD1875-5DF1-4979-9D98-9E76FCCC692C

P304

Q34898930-154C802E-9DDB-4C50-B10C-D9E045356617

P31

Q34898930-3E00125A-3E6C-46EF-A352-200AF1862A81

P356

Q34898930-B9E13A53-00BF-475C-8250-691D921B0F6D

P407

Q34898930-9948FAFA-88C6-46C2-89B4-40ED8C58E4C6

P433

Q34898930-E5CAF000-2245-4A51-9545-6AAE3676D736

P478

Q34898930-6372FFB7-B760-4C39-A512-7F683092882C

P577

Q34898930-896C8D81-085F-4513-AEE4-C25235A67653

P5875

Q34898930-307AFF00-180B-4B3F-94ED-8349D91D3BB8

P698

Q34898930-4EB107E5-2A40-4E61-BF40-E06A5AEB3939

P921

Q34898930-8F8C56E7-BE2A-4EFC-A1D3-225A2AE67321

P932

Q34898930-31BDD100-4AF4-4865-8C6B-88594E011A7F

P356

1078-0432.CCR-08-0221

P1433

Clinical Cancer Research

P1476

A phase II trial of 17-allylam ...... ry metastatic prostate cancer.

@en

P2093

Charles Erlichman

http://www.w3.org/2001/XMLSchema#string

David W Hillman

http://www.w3.org/2001/XMLSchema#string

Elisabeth I Heath

http://www.w3.org/2001/XMLSchema#string

Fazlul Sarkar

http://www.w3.org/2001/XMLSchema#string

Felicity Harper

http://www.w3.org/2001/XMLSchema#string

Glenn Liu

http://www.w3.org/2001/XMLSchema#string

Henry C Pitot

http://www.w3.org/2001/XMLSchema#string

Melvin Gaskins

http://www.w3.org/2001/XMLSchema#string

Michael A Carducci

http://www.w3.org/2001/XMLSchema#string

Roberto Pili

http://www.w3.org/2001/XMLSchema#string

P2860

Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells

Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent

Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone

The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Tumor-suppressive maspin regulates cell response to oxidative stress by direct interaction with glutathione S-transferase.

Hsp90's secrets unfold: new insights from structural and functional studies.

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators.

P304

7940-7946

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-0221

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23560059

http://www.w3.org/2001/XMLSchema#string

P698

19047126

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

3085545

http://www.w3.org/2001/XMLSchema#string